Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03387085
Title QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NantKwest, Inc.
Indications

triple-receptor negative breast cancer

Therapies

ETBX-051

Aldoxorubicin

ETBX-061

Cisplatin

Cyclophosphamide

haNK cells

GI-4000

Bevacizumab

ALT-803

Fluorouracil

ETBX-011

Oxaliplatin

Capecitabine

Leucovorin

GI-6301

Nab-paclitaxel

Avelumab

GI-6207

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.